NXTC · Insider Trading
NextCure, Inc. Common Stock
Every open-market purchase and sale reported by NXTC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Jinsheng Ren | — | Sell | −180,000 | −$1.11M |
| 2026-08-03 | Daniel Schneeberger | 10%+ Owner | Buy | +658,306 | +$3.25M |
| 2026-07-29 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy | +35,216 | +$175.43K |
| 2026-06-22 | Anne Elizabeth Borgman | Director | A | +2,340 deriv. | — |
| 2026-06-22 | Ellen Feigal | Director | A | +2,340 deriv. | — |
| 2026-06-22 | Elaine V Jones | Director | A | +2,340 deriv. | — |
| 2026-06-22 | David S Kabakoff | Director | A | +3,510 deriv. | — |
| 2026-06-22 | Stephen W Webster | Director | A | +2,340 deriv. | — |
| 2026-06-22 | John G Houston | Director | A | +2,340 deriv. | — |
| 2026-02-03 | Timothy Mayer | Chief Operating Officer | A | +14,670 deriv. | — |
| 2026-02-03 | Udayan Guha | Chief Medical Officer | A | +14,670 deriv. | — |
| 2026-02-03 | Kevin G. Shaw | Sr VP, General Counsel | A | +8,270 deriv. | — |
| 2026-02-03 | Sourav Kundu | Sr VP, Dev. & Mfg. | A | +8,270 deriv. | — |
| 2026-02-03 | Michael Richman | President & CEO | A | +38,190 deriv. | — |
| 2026-02-03 | Steven P. Cobourn | Chief Financial Officer | A | +14,670 deriv. | — |
| 2025-06-24 | Elaine V Jones | Director | A | +18,700 deriv. | — |
| 2025-06-24 | John G Houston | Director | A | +18,700 deriv. | — |
| 2025-06-24 | Ellen Feigal | Director | A | +18,700 deriv. | — |
| 2025-06-24 | David S Kabakoff | Director | A | +28,050 deriv. | — |
| 2025-06-24 | Stephen W Webster | Director | A | +18,700 deriv. | — |
| 2025-06-24 | Anne Elizabeth Borgman | Director | A | +18,700 deriv. | — |
| 2025-02-03 | Sourav Kundu | Sr VP, Dev. & Mfg. | A | +66,125 deriv. | — |
| 2025-02-03 | Kevin G. Shaw | Sr VP, General Counsel | A | +66,125 deriv. | — |
| 2025-02-03 | Michael Richman | President & CEO | A | +305,500 deriv. | — |
| 2025-02-03 | Sol Langermann | Chief Scientific Officer | A | +117,375 deriv. | — |
| 2025-02-03 | Timothy Mayer | Chief Operating Officer | A | +117,375 deriv. | — |
| 2025-02-03 | Steven P. Cobourn | Chief Financial Officer | A | +117,375 deriv. | — |
| 2024-06-21 | David S Kabakoff | Director | A | +28,050 deriv. | — |
| 2024-06-21 | Elaine V Jones | Director | A | +18,700 deriv. | — |
| 2024-06-21 | John G Houston | Director | A | +18,700 deriv. | — |
| 2024-06-21 | Ellen Feigal | Director | A | +18,700 deriv. | — |
| 2024-06-21 | Stephen W Webster | Director | A | +18,700 deriv. | — |
| 2024-06-21 | Anne Elizabeth Borgman | Director | A | +18,700 deriv. | — |
| 2024-04-02 | Steven P. Cobourn | Chief Financial Officer | A | +93,900 deriv. | — |
| 2024-04-02 | Sol Langermann | Chief Scientific Officer | A | +93,900 deriv. | — |
| 2024-04-02 | Sourav Kundu | Sr VP, Dev. & Mfg. | A | +52,900 deriv. | — |
| 2024-04-02 | Kevin G. Shaw | Sr VP, General Counsel | A | +93,900 deriv. | — |
| 2024-04-02 | Han Myint | Chief Medical Officer | A | +93,900 deriv. | — |
| 2024-04-02 | Michael Richman | President & CEO | A | +244,400 deriv. | — |
| 2024-04-02 | Timothy Mayer | Chief Operating Officer | A | +93,900 deriv. | — |
| 2024-02-01 | Kevin G. Shaw | Sr VP, General Counsel | A | +66,125 deriv. | — |
| 2024-02-01 | Steven P. Cobourn | Chief Financial Officer | A | +117,375 deriv. | — |
| 2024-02-01 | Michael Richman | President & CEO | A | +305,500 deriv. | — |
| 2024-02-01 | Sol Langermann | Chief Scientific Officer | A | +117,375 deriv. | — |
| 2024-02-01 | Sourav Kundu | Sr VP, Dev. & Mfg. | A | +66,125 deriv. | — |
| 2024-02-01 | Han Myint | Chief Medical Officer | A | +117,375 deriv. | — |
| 2024-02-01 | Timothy Mayer | Chief Operating Officer | A | +117,375 deriv. | — |
| 2023-06-23 | Chau Quang Khuong | Director | A | +14,250 deriv. | — |
| 2023-06-23 | Elaine V Jones | Director | A | +14,250 deriv. | — |
| 2023-06-23 | Stephen W Webster | Director | A | +14,250 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Daniel Schneeberger | 10%+ Owner | 608,266 | $3.18M |
| ADAR1 Capital Management, LLC | 10%+ Owner | 389,856 | $2.04M |
| Jinsheng Ren | — | 308,636 | $1.61M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NXTC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.